Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals

APOEε4 potentiates the relationship between amyloid-β and tau pathologies

(2020) Joseph Therriault et al.   MOLECULAR PSYCHIATRY

Apolipoprotein E ε4 allele effects on longitudinal cognitive trajectories are sex and age dependent

(2019) Owen A. Williams et al.   Alzheimers & Dementia

Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele

(2019) Valentina Ghisays et al.   Alzheimers & Dementia

Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β

(2019) Joseph Therriault et al.   JAMA Neurology

White matter reference region in PET studies of11C-Pittsburgh Compound B uptake: effects of age and amyloid-β deposition

(2018) Val J. Lowe et al.   JOURNAL OF NUCLEAR MEDICINE

Neurogenetic contributions to amyloid beta and tau spreading in the human cortex

(2018) Jorge Sepulcre et al.   NATURE MEDICINE

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

(2017) Yang Shi et al.   NATURE

The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests

(2016) Chatchawan Rattanabannakit et al.   JOURNAL OF ALZHEIMERS DISEASE

Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan

(2016) Julie Gonneaud et al.   NEUROLOGY

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Developments in Tau PET Imaging

(2014) Eduardo Rigon Zimmer et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study

(2014) Clifford R Jack et al.   LANCET NEUROLOGY

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease

(2012) Adam S. Fleisher et al.   NEUROBIOLOGY OF AGING